Human epidermal growth factor receptor 2 (Her-2)-positive breast cancer has been for a long time an aggressive with poor prognosis disease. However, thanks to targeted therapies, prolonged survival is possible, even in metastatic patients. Nevertheless, while the prognosis has improved, metastatic disease is still not curable. The authors report the original case of a 73-year-old Caucasian woman who presented with a T1a hormonal receptors and Her-2 positive multimetastatic (liver, bones, pleural, adrenal gland, and nodes). The patient began chemotherapy with docetaxel + pertuzumab + trastuzumab regimen with good tolerance, and no grade 3 or more adverse effect. Ca 15-3 level before treatment was high at 729 ng/ml and carcinoembryonic antigen (CEA) was at 1.2 ng/ml. After six cycles of chemotherapy, tomography positron emission scan showed metabolic complete response. Ca 15-3 level decreased to 35 ng/ml and CEA at 0.9 ng/ml. The patient is continuing pertuzumab + trastuzumab. Docetaxel associated to pertuzumab and trastuzumab in metastatic Her2-positive breast cancer is effective and can lead to complete response.